09
Mar

When the FDA rejected AcelRx’s drug/device Zalviso for pain last summer, the biotech said no new trials were required–suggesting it could be back in front of regulators quickly–and investors cut the value of shares by more than 30%. This morning the biotech said a new study is needed after all, and investors responded by sending shares down by more than 40%.

…read more

Source: AcelRx hammered (again) after FDA demands a new Zalviso study after all

    

0 No comments